SHPMY Shanghai Pharmaceuticals Holding Co., Ltd — dividend yield, history & ex-dividend dates
Shanghai Pharmaceuticals Holding Co., Ltd. operates as an investment holding enterprise deeply embedded in China's pharmaceutical and healthcare industries. The company oversees a full range of activities, from the research and development of new drugs to their manufacturing, nationwide distribution, and retail sales of a diverse array of pharmaceutical and health-related products. Its operations are strategically managed across four primary divisions: Production, Distribution, Retail, and Other services. The company's extensive product catalog includes chemical compounds, biochemicals, traditional Chinese remedies, general healthcare items, and medical devices. These offerings are designed to address a broad spectrum of medical conditions, encompassing oncology, cardiovascular and cerebrovascular issues, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory conditions. Notably, their portfolio boasts over 700 distinct pharmaceutical formulations. Beyond product development and manufacturing, Shanghai Pharmaceuticals is a significant player in comprehensive pharmaceutical supply chain management. This involves sophisticated distribution, warehousing, logistics, and various value-added services, all provided to a wide range of clients including drug manufacturers and healthcare providers such as hospitals, other wholesalers, and individual retail pharmacies. Moreover, the company maintains a substantial retail footprint, managing an extensive network of roughly 2,000 chain pharmacies spread across 24 provinces, alongside a thriving online drug commerce platform. Its diverse service offerings further extend to consulting, asset management, facilitating clinical trials, offering medical assistance, educating both medical professionals and patients, handling electronic prescriptions, and pioneering remote and cloud-based hospital solutions. Established in Shanghai in 1994, Shanghai Pharmaceuticals Holding Co., Ltd. functions as a subsidiary under Shanghai Pharmaceutical (Group) Co., Ltd.
Dividend Snapshot
Key Metrics
Current Yield
2.05%
At the Sep 14, 2026 price
The annual dividend as a percentage of the share price. A 3% yield is about $3 of dividends a year for every $100 invested at today's price.Annualized Dividend
$0.1487
The most recent payment scaled to a full year by how often it's paid. A $0.25 quarterly dividend annualizes to $1.00.Frequency
I
How often the dividend is paid: Q = quarterly (4x a year), M = monthly, S = semi-annual, A = annual.Rank Score
53.8
As of Sep 14, 2026
Our 0-100 house score blending yield quality, payout sustainability (the trailing-twelve-month payout ratio), profitability (TTM return on equity), valuation (TTM price-to-book) and payment reliability, recomputed daily. Higher means a stronger profile on those factors in our model — a research score, not advice or a recommendation to buy.RSI (14)
33
As of Sep 14, 2026
Relative Strength Index (0-100), a price-momentum gauge. Above 70 is often called 'overbought', below 30 'oversold'. A technical signal, not a dividend metric.52-Week Range
$7.04 – $8.30
Closes through Sep 11, 2026
The lowest and highest price over the past year — shows where today's price sits in its recent range.Payout Ratio (TTM)
61.50%
12 months to Jun 30, 2026 (Q2 FY2026)
The share of earnings paid out as dividends over the trailing twelve months (TTM): dividends paid divided by net income across the company's four most recent reported quarters, dated by the latest quarter end. A fiscal-year tag such as FY2025 means only annual figures were available. Lower leaves more cushion; above 100% means paying out more than the company earned. It shows n/a for funds and when net income over the period was negative; for REITs and BDCs it is marked EPS-based, since they are judged on FFO/AFFO or net investment income instead.Years Paying
12
How many years of payments we have on record. This can understate very long histories where our data doesn't reach far enough back.Price / Book (TTM)
0.77
Price as of Sep 14, 2026; latest reported book value
Price-to-book ratio: the share price on the date shown divided by the latest reported book value per share. A rough valuation gauge, most useful for asset-heavy sectors like REITs, banks and insurers.S.A.F.E. Dividend Read
Quote & Key Data
Dividend Growth
Why the Yield Moved (90 Days)
SHPMY's dividend yield fell from 2.22% to 2.05% over the past ~90 days (-0.17 pp). Of that move, -0.28 pp came from changes in the dividend rate and +0.11 pp from the share price ($7.60 on Jun 16, 2026 → $7.24 on Sep 14, 2026). A yield that rises because the price fell is not an improvement in the payout itself.
Yield vs Its Own History
Across 326 daily observations over the past 15 months (through Sep 11, 2026), SHPMY's current yield is higher than approximately 18% of them. Our stored price history for SHPMY covers the past 15 months; 3- and 5-year averages are not yet computable from it and are deliberately not shown.
Adjusted Price History
Dividend History
Dividend Payment History
Ex-dividend calendar →| Amount | Type | Declared | Ex-Date | Record | Pay |
|---|---|---|---|---|---|
| $0.0744 I | Regular upcoming, declared | Sep 03, 2026 | Sep 17, 2026 | Sep 17, 2026 | Nov 12, 2026 |
| $0.2577 S | Regular | Jun 26, 2026 | Jul 16, 2026 | Jul 16, 2026 | Sep 14, 2026 |
| $0.0844 S | Regular | Dec 10, 2025 | Dec 31, 2025 | Dec 31, 2025 | Feb 23, 2026 |
| $0.2025 A | Regular | Jun 30, 2025 | Jul 17, 2025 | Jul 17, 2025 | Sep 09, 2025 |
| $0.0561 S | Regular | Sep 04, 2024 | Sep 19, 2024 | Sep 19, 2024 | Nov 12, 2024 |
| $0.2819 S | Regular | Jul 08, 2024 | Jul 19, 2024 | Jul 19, 2024 | Sep 11, 2024 |
| $0.4210 A | Regular | - | Jul 17, 2023 | Jul 18, 2023 | Sep 12, 2023 |
| $0.3120 A | Regular | - | Jul 21, 2022 | Jul 22, 2022 | Sep 13, 2022 |
| $0.3700 A | Regular | - | Jul 14, 2021 | Jul 15, 2021 | Sep 13, 2021 |
| $0.3104 A | Regular | - | Jul 15, 2020 | Jul 16, 2020 | Sep 08, 2020 |
| $0.2995 A | Regular | - | Jul 11, 2019 | Jul 12, 2019 | Sep 09, 2019 |
| $0.2938 A | Regular | - | Jul 11, 2018 | Jul 12, 2018 | Sep 10, 2018 |
| $0.2642 A | Regular | - | Jul 10, 2017 | Jul 12, 2017 | Sep 05, 2017 |
| $0.2505 A | Regular | - | Jul 13, 2016 | - | - |
| $0.2371 A | Regular | - | Jun 15, 2015 | - | - |
| $0.2112 A | Regular | - | May 22, 2014 | - | - |
Peer Comparison
Selected Medical - Distribution dividend payers we cover, strongest DividendRank first — for context, not a recommendation.
| Ticker | Name | Yield | 5-Yr Growth | Streak | Rank |
|---|---|---|---|---|---|
| MEPDF | MediPal Holdings Corporation | 3.05% | 1.8% | 3 yrs | 78 |
| ARHCF | Alfresa Holdings Corporation | 3.33% | -1.5% | 0 yrs | 78 |
| IUSDF | AS ONE Corporation | 3.05% | -1.0% | 4 yrs | 77 |
| ALFRY | Alfresa Holdings Corporation | 3.32% | -2.0% | 0 yrs | 74 |
Related Guides & Lists
SHPMY dividend — frequently asked questions
Does Shanghai Pharmaceuticals Holding Co., Ltd pay a dividend?
Yes. Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) currently pays a dividend. The annualized dividend is about $0.15 per share, a yield of approximately 2.05%.
What is Shanghai Pharmaceuticals Holding Co., Ltd's dividend yield?
Shanghai Pharmaceuticals Holding Co., Ltd's dividend yield is approximately 2.05%, based on the most recent regular payment annualized against the current share price. Yields move as the share price changes.
When is Shanghai Pharmaceuticals Holding Co., Ltd's next ex-dividend date?
The next declared ex-dividend date for Shanghai Pharmaceuticals Holding Co., Ltd is September 17, 2026. The associated payment is $0.0744 per share; you must own the shares before the ex-dividend date to receive it.
How long has Shanghai Pharmaceuticals Holding Co., Ltd paid dividends?
Shanghai Pharmaceuticals Holding Co., Ltd has 12 years of dividend payments on record.
Data updated Sep 14, 2026. This research page is generated from Dividendly's structured market and dividend dataset using the approach described on our methodology and data sources pages. Data is automatically validated using defined rules and may also be periodically reviewed. Research only, not investment advice. Spotted a data error? Report it.